Natixis’s Catalyst Pharmaceutical CPRX Stock Holding History

Natixis’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-87,572	Closed	-$1.73M	–	1157
2025 Q3	$1.73M	Buy	+87,572	New	+$1.8M	0.01%	592
2023 Q4	–	Sell	-108,300	Closed	-$1.27M	–	1067
2023 Q3	$1.27M	Buy	+108,300	New	+$1.45M	0.01%	465
2022 Q2	–	Sell	-225,377	Closed	-$1.87M	–	1192
2022 Q1	$1.87M	Sell	225,377 -10,643	-5%	-$75.2K	0.01%	766
2021 Q4	$1.6M	Buy	+236,020	New	+$1.55M	0.01%	831

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's CPRX Position: Q4 2025 in Review

Natixis sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 87,572 shares — an estimated $1.73M sold.

Natixis first reported a position in CPRX in Q4 2021 and held it in 4 quarters. The position peaked at $1.87M in Q1 2022. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

Natixis reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Natixis sold 87,572 Catalyst Pharmaceutical shares in Q4 2025, an estimated $1.73M.
Natixis first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 4 quarters.
Natixis's Catalyst Pharmaceutical position peaked at $1.87M in Q1 2022.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Natixis's 13F filing for Q4 2025, filed 13 Feb 2026.